Related Experiment Video
Updated: Jul 18, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Indications for cardiac defibrillators in patients with congestive heart failure
Isaac Pourati1, Lawrence Rosenthal
1Department of Medicine, Division of Cardiovascular Medicine, Cardiac Pacing and Electrophysiology, UMass Memorial Medical Center, 55 Lake Avenue North, Worcester, MA 01655, USA.
Insights
Sudden cardiac death (SCD) is a major risk for heart failure patients. Implantable cardiac defibrillators (ICDs) are proven to prevent SCD, with trials expanding their use for primary prevention.
Area of Science:
- Cardiology
- Medical Devices
- Clinical Trials
Background:
- Sudden cardiac death (SCD) is a leading cause of mortality in heart failure patients.
- Left ventricular dysfunction is a key risk factor associated with SCD.
- Implantable cardiac defibrillators (ICDs) offer a therapeutic intervention for SCD prevention.
Purpose of the Study:
- To review clinical trials that have shaped current practice guidelines for ICD implantation.
- To highlight the evolution of ICD indications from secondary to primary prevention of SCD.
- To discuss the role of device therapy in managing patients at risk for SCD.
Main Methods:
- Systematic review of pivotal clinical trials.
- Analysis of patient populations and outcomes related to ICD therapy.
- Evaluation of evidence supporting current guidelines for SCD prevention.
Main Results:
- Clinical trials have demonstrated the efficacy of ICDs in reducing SCD incidence.
- Evidence supports the expansion of ICD use for primary prevention in selected heart failure patients.
- Current guidelines incorporate device therapy based on trial data.
Conclusions:
- Implantable cardiac defibrillators are crucial for preventing sudden cardiac death in heart failure.
- Ongoing research and clinical trials continue to refine patient selection for ICD therapy.
- Device therapy plays a vital role in the management of cardiovascular mortality.
Abstract:
Sudden cardiac death (SCD) is a significant cause of mortality in patients suffering from heart failure and left ventricular dysfunction. Implantable cardiac defibrillators have been shown to effectively reduce the incidence of SCD in this population. Multiple clinical trials have redefined the indications and patient profiles for their use: from secondary prevention to primary prevention of SCD. In this article, we will review the clinical trials contributing to the current practice guidelines, which include device therapy.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiopulmonary Resuscitation III: AED Use
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care
